Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.Year to date, Protagonist Therapeutics' stock has gained around 132%, as per data from Benzinga Pro.Partnership May Evolve Into Full OwnershipJohnson & Johnson and Protagonist already share a collaboration to develop an oral therapy targeting plaque psoriasis and u ...

Exclusive: Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that would solidify the companies’ existing partnership in creating a treatment for ulcerative colitis https://t.co/BNb7Po7tF7 ...

Welcome back to Money Movers. Take a look at the XBI biotech ETF on pace for its best year since 2020. And news breaking earlier from the Wall Street Journal that Johnson and Johnson is looking to buy Protagonist Therapeutics.Our ne next guest is a top shareholder in Protagonist and a longtime investor in the biotech space. Joining us now, RTW Investments managing partner and CIO, Dr. . Rod Wong.Dr. . Thank you for being here today. Um, so there's been a a string of acquisitions in this space in in recent w ...

J&J is in talks to purchase Protagonist Therapeutics, the Wall Street Journal reported, citing people familiar with the matter. https://t.co/ykJVKinOA4 ...

Group 1: Global Market Performance - U.S. equity markets showed slight gains on October 10, 2025, with the Dow Jones Industrial Average up 0.3%, and both the Nasdaq Composite and S&P 500 rising 0.2% [2] - In contrast, Asian markets faced significant declines, with the NASDAQ Golden Dragon China Index dropping 2.6%, the largest single-day decline since August 27th, and the Hong Kong Hang Seng index falling 1.8% [3] Group 2: Johnson & Johnson and Protagonist Therapeutics - Johnson & Johnson is reportedly in talks to acquire Protagonist Therapeutics, leading to a 10% surge in Protagonist's shares before a temporary halt due to volatility [4] - The two companies have an existing partnership focused on co-developing a treatment for ulcerative colitis, and the acquisition could enhance J&J's portfolio with experimental therapies like rusfertide [4] Group 3: Geopolitical Developments - Former President Trump expressed concerns over China's actions regarding rare earth export controls, which have expanded to include five additional elements, particularly affecting the semiconductor industry [5] - Switzerland's Foreign Minister expressed optimism for a free trade agreement with China by early 2026, while the EU is planning a new trade proposal with the U.S. amid perceived maximalist demands from Washington [6] Group 4: Middle East Ceasefire and European Politics - Leaders from Britain, France, and Germany welcomed a Middle East ceasefire agreement and the planned release of hostages, with Trump receiving thanks for his diplomatic efforts [7][8] - French political dynamics remain turbulent, particularly regarding pension reform, with ongoing difficulties in forming a consensus government [9]

Protagonist Therapeutics (NASDAQ:PTGX), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the company. Citing people familiar with the matter, the publication noted ...

Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter. ...

The two companies are already codeveloping a treatment for ulcerative colitis. ...

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]

We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.'s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance. 10 Best Healthcare Dividend Stocks To Buy Protagonist Therapeutics (PTGX) presents a compelling investment case following strong clinical progress and underappr ...